LYTIR

Insider · SEC Form 4 · 10% Owner

AH Bio Fund IV, L.P.

In the 12 months to Nov 19, 2026, on the open market: bought $19.8M of BRVE. Filed 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

  1. BRVEBought: Braveheart Bio, Inc. Aug 7, 2026 1,100,000 shares filed Aug 11, 2026 10,232,420 shares held indirectly after, as filed filing $19.8M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. BRVEAH Bio Fund IV, L.P. filed Aug 14, 2026 Schedule 13D may seek influence 10,232,420 shares issuer: Braveheart Bio, Inc. filing 11.4%

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • BRVE: conversion (code C), 1 entry, Aug 7, 2026
Code C
A conversion of a derivative security, such as preferred stock or units, into shares.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.